Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

PRECISION delivers on the PROMIS of mpMRI in early detection

Nature Reviews Urology volume 15, pages 529–530 (2018)Cite this article

Subjects

Use of multiparametric MRI for detection of prostate cancer has been increasing and two recent studies have provided high-quality evidence advocating its integration into the diagnostic protocol. A new paradigm for detection of prostate cancer in the era of PROMIS and PRECISION should be adopted globally.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The proposed new paradigm for early detection of prostate cancer in the PROMIS and PRECISION era.

References

  1. Moore, C. M. et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur. Urol. 64, 544–552 (2013).

    Article  PubMed  Google Scholar 

  2. Weinreb, J. C. et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur. Urol. 69, 16–40 (2016).

    Article  PubMed  Google Scholar 

  3. Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

    Article  PubMed  Google Scholar 

  4. Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).

    Article  PubMed  Google Scholar 

  5. Panebianco, V. et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what’s next? Eur. Urol. 74, 48–54 (2018).

  6. Murphy, D. G. et al. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 113, 186–188 (2014).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia

    Tatenda Nzenza & Declan G. Murphy

  2. Sir Peter MacCallum Department of Oncology. University of Melbourne, Parkville, Australia

    Tatenda Nzenza & Declan G. Murphy

Authors
  1. Tatenda Nzenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Declan G. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Declan G. Murphy.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nzenza, T., Murphy, D.G. PRECISION delivers on the PROMIS of mpMRI in early detection. Nat Rev Urol 15, 529–530 (2018). https://doi.org/10.1038/s41585-018-0046-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0046-5

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing